Cirrhotic-extracellular matrix attenuates aPD-1 treatment response by initiating immunosuppressive neutrophil extracellular traps formation in hepatocellular carcinoma
ConclusionsCirrhotic-ECM modulated a NETs enriched TME in HCC, produced an immune suppressive TME and weakened ICI efficiency. Col1 receptor DDR1 could be a potential target synergically used with ICI to overcome ECM mediated ICI resistance. These provide a mechanical insight and novel strategy to overcome the ICI resistance of HCC. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - February 22, 2024 Category: Cancer & Oncology Source Type: research
Comparison of the efficacy among nilotinib, dasatinib, flumatinib and imatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients: A real-world multi-center retrospective study
There are limited data comprehensively comparing therapy responses and outcomes among nilotinib, dasatinib, flumatinib and imatinib for newly diagnosed chronic-phase chronic myeloid leukemia in a real-world setting. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 14, 2024 Category: Hematology Authors: Xiaoshuai Zhang, Na Xu, Yunfan Yang, Hai Lin, Bingcheng Liu, Xin Du, Xiaoli Liu, Rong Liang, Chunyan Chen, Jian Huang, Huanling Zhu, Ling Pan, Xiaodong Wang, Guohui Li, Zhuogang Liu, Yanqing Zhang, Zhenfang Liu, Jianda Hu, Chunshui Liu, Fei Li, Wei Yang, Source Type: research
Analysis of the contributing role of drug transport across biological barriers in the development and treatment of chemotherapy-induced peripheral neuropathy
ConclusionsHence, high unbound drug intracellular and extracellular exposure at target sites, driven by an interplay of drug transport across the endothelial and parenchymal cellular barriers, is a predisposing factor to CIPN development for CIPN-positive drugs. Critical drug-specific features of unbound drug disposition at various CIPN- sites provide invaluable insights into understanding the pharmacological/toxicological effects at the target-sites which will inform new strategies for monitoring and treatment of CIPN. (Source: Fluids and Barriers of the CNS)
Source: Fluids and Barriers of the CNS - February 8, 2024 Category: Neuroscience Source Type: research
Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia
CONCLUSION: Imatinib could result in a decline in eGFR which was clinically similar to early-stage CKD patients. We did not observe significant kidney function deterioration in patients receiving 2GTKIs including dasatinib and nilotinib. We recommend close renal function monitoring in patients receiving imatinib, especially for elderly patients with lower baseline eGFR and hypertension.PMID:38281820 | DOI:10.1016/j.clml.2023.12.004 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 28, 2024 Category: Cancer & Oncology Authors: Özge Sönmez Nurg ül Özgür Yurttaş İlker İhtiyaroğlu Halil Mete Çakır Zeynep Atl ı Tu ğrul Elverdi Ay şe Salihoğlu Nurhan Seyahi Muhlis Cem Ar Şeniz Öngören Zafer Ba şlar Teoman Soysal Ahmet Emre E şkazan Source Type: research
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib
AbstractPatients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib may experience arterial occlusive events (AOEs). It is currently recommended to thoroughly assess cardiovascular risk factors before treating CML. We identified 455 consecutive CML adult patients, 335 treated with nilotinib and 120 with ponatinib; 380 patients without previous cardiovascular diseases or diabetes were stratified according to the Systematic Coronary Risk Evaluation (SCORE2) and SCORE2-Older Persons (SCORE2-OP). This updated algorithm from the European Society of Cardiology (ESC) estimates a 10-year risk of fatal and non-...
Source: Annals of Hematology - January 20, 2024 Category: Hematology Source Type: research
A glycosylation-related gene signature predicts prognosis, immune microenvironment infiltration, and drug sensitivity in glioma
Glioma represents the most common primary cancer of the central nervous system in adults. Glycosylation is a prevalent post-translational modification that occurs in eukaryotic cells, leading to a wide array of modifications on proteins. We obtained the clinical information, bulk RNA-seq data, and single-cell RNA sequencing (scRNA-seq) from The Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), Gene Expression Omnibus (GEO), and Repository of Molecular Brain Neoplasia Data (Rembrandt) databases. RNA sequencing data for normal brain tissues were accessed from the Genotype-Tissue Expression (GTEx) database. Then...
Source: Frontiers in Pharmacology - January 16, 2024 Category: Drugs & Pharmacology Source Type: research
Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid Leukemia
Clin Lymphoma Myeloma Leuk. 2023 Dec 29:S2152-2650(23)02200-0. doi: 10.1016/j.clml.2023.12.011. Online ahead of print.ABSTRACTLong-term survival outcomes of patients with chronic myeloid leukemia in the chronic phase are now similar to those of the general population, following the introduction of ABL1 tyrosine kinase inhibitors (TKIs). Approximately 40% to 80% of patients with chronic myeloid leukemia successfully achieved treatment-free remission after the first attempt of TKI discontinuation (TFR1), after achieving a durable deep molecular response. However, the possibility of achieving treatment-free remission after a ...
Source: Clinical Lymphoma and Myeloma - January 9, 2024 Category: Cancer & Oncology Authors: Hiroshi Ureshino Kazuharu Kamachi Shinya Kimura Source Type: research
SOHO State of the Art Updates and Next Questions: Chronic Myeloid Leukemia and Pregnancy: "Per Aspera Ad Astra"
Clin Lymphoma Myeloma Leuk. 2023 Dec 12:S2152-2650(23)02189-4. doi: 10.1016/j.clml.2023.11.011. Online ahead of print.ABSTRACTChronic myeloid leukemia (CML) has evolved from an invariably fatal disease to a chronic disorder that can be treated with targeted drugs and allows survival expectations approaching age-matched controls. Thus, pregnancy and conception in CML should not be precluded anymore; however, to ensure the well-being of both the mother and the developing fetus careful planning and management are required. Tyrosine Kinase Inhibitors (TKIs) are not genotoxic or carcinogenic but can pose a risk to the developin...
Source: Clinical Lymphoma and Myeloma - December 27, 2023 Category: Cancer & Oncology Authors: Elisabetta Abruzzese Malgorzata Monika Trawinska Paolo De Fabritiis Simona Bernardi Source Type: research
SOHO State of the Art Updates and Next Questions: Chronic Myeloid Leukemia and Pregnancy: "Per Aspera Ad Astra"
Clin Lymphoma Myeloma Leuk. 2023 Dec 12:S2152-2650(23)02189-4. doi: 10.1016/j.clml.2023.11.011. Online ahead of print.ABSTRACTChronic myeloid leukemia (CML) has evolved from an invariably fatal disease to a chronic disorder that can be treated with targeted drugs and allows survival expectations approaching age-matched controls. Thus, pregnancy and conception in CML should not be precluded anymore; however, to ensure the well-being of both the mother and the developing fetus careful planning and management are required. Tyrosine Kinase Inhibitors (TKIs) are not genotoxic or carcinogenic but can pose a risk to the developin...
Source: Clinical Lymphoma and Myeloma - December 27, 2023 Category: Cancer & Oncology Authors: Elisabetta Abruzzese Malgorzata Monika Trawinska Paolo De Fabritiis Simona Bernardi Source Type: research
SOHO State of the Art Updates and Next Questions: Chronic Myeloid Leukemia and Pregnancy: "Per Aspera Ad Astra"
Clin Lymphoma Myeloma Leuk. 2023 Dec 12:S2152-2650(23)02189-4. doi: 10.1016/j.clml.2023.11.011. Online ahead of print.ABSTRACTChronic myeloid leukemia (CML) has evolved from an invariably fatal disease to a chronic disorder that can be treated with targeted drugs and allows survival expectations approaching age-matched controls. Thus, pregnancy and conception in CML should not be precluded anymore; however, to ensure the well-being of both the mother and the developing fetus careful planning and management are required. Tyrosine Kinase Inhibitors (TKIs) are not genotoxic or carcinogenic but can pose a risk to the developin...
Source: Clinical Lymphoma and Myeloma - December 27, 2023 Category: Cancer & Oncology Authors: Elisabetta Abruzzese Malgorzata Monika Trawinska Paolo De Fabritiis Simona Bernardi Source Type: research
SOHO State of the Art Updates and Next Questions: Chronic Myeloid Leukemia and Pregnancy: "Per Aspera Ad Astra"
Clin Lymphoma Myeloma Leuk. 2023 Dec 12:S2152-2650(23)02189-4. doi: 10.1016/j.clml.2023.11.011. Online ahead of print.ABSTRACTChronic myeloid leukemia (CML) has evolved from an invariably fatal disease to a chronic disorder that can be treated with targeted drugs and allows survival expectations approaching age-matched controls. Thus, pregnancy and conception in CML should not be precluded anymore; however, to ensure the well-being of both the mother and the developing fetus careful planning and management are required. Tyrosine Kinase Inhibitors (TKIs) are not genotoxic or carcinogenic but can pose a risk to the developin...
Source: Clinical Lymphoma and Myeloma - December 27, 2023 Category: Cancer & Oncology Authors: Elisabetta Abruzzese Malgorzata Monika Trawinska Paolo De Fabritiis Simona Bernardi Source Type: research
SOHO State of the Art Updates and Next Questions: Chronic Myeloid Leukemia and Pregnancy: "Per Aspera Ad Astra"
Clin Lymphoma Myeloma Leuk. 2023 Dec 12:S2152-2650(23)02189-4. doi: 10.1016/j.clml.2023.11.011. Online ahead of print.ABSTRACTChronic myeloid leukemia (CML) has evolved from an invariably fatal disease to a chronic disorder that can be treated with targeted drugs and allows survival expectations approaching age-matched controls. Thus, pregnancy and conception in CML should not be precluded anymore; however, to ensure the well-being of both the mother and the developing fetus careful planning and management are required. Tyrosine Kinase Inhibitors (TKIs) are not genotoxic or carcinogenic but can pose a risk to the developin...
Source: Clinical Lymphoma and Myeloma - December 27, 2023 Category: Cancer & Oncology Authors: Elisabetta Abruzzese Malgorzata Monika Trawinska Paolo De Fabritiis Simona Bernardi Source Type: research
SOHO State of the Art Updates and Next Questions: Chronic Myeloid Leukemia and Pregnancy: "Per Aspera Ad Astra"
Clin Lymphoma Myeloma Leuk. 2023 Dec 12:S2152-2650(23)02189-4. doi: 10.1016/j.clml.2023.11.011. Online ahead of print.ABSTRACTChronic myeloid leukemia (CML) has evolved from an invariably fatal disease to a chronic disorder that can be treated with targeted drugs and allows survival expectations approaching age-matched controls. Thus, pregnancy and conception in CML should not be precluded anymore; however, to ensure the well-being of both the mother and the developing fetus careful planning and management are required. Tyrosine Kinase Inhibitors (TKIs) are not genotoxic or carcinogenic but can pose a risk to the developin...
Source: Clinical Lymphoma and Myeloma - December 27, 2023 Category: Cancer & Oncology Authors: Elisabetta Abruzzese Malgorzata Monika Trawinska Paolo De Fabritiis Simona Bernardi Source Type: research
Identification of common genes and pathways underlying imatinib and nilotinib treatment in CML: a Bioinformatics Study
Nucleosides Nucleotides Nucleic Acids. 2023 Dec 20:1-21. doi: 10.1080/15257770.2023.2296021. Online ahead of print.ABSTRACTImatinib (IMA) and nilotinib are the first and second generations of BCR-ABL tyrosine kinase inhibitors, which widely applied in chronic myeloid leukemia (CML) treatment. Here we aimed to provide new targets for CML treatment by transcriptome analysis. Microarray data GSE19567 was downloaded and analyzed from Gene Expression Omnibus (GEO) to identify common genes, which are downregulated or upregulated in K562-imatinib and K562-nilotinib treated cells. The differentially expressed genes (DEGs) were ass...
Source: Nucleosides, Nucleotides and Nucleic Acids - December 20, 2023 Category: Biochemistry Authors: Yalda Hekmatshoar Yalda Rahbar Saadat Tulin Ozkan Sureyya Bozkurt Aynur Karadag Gurel Source Type: research
